Efficacy and Safety of Delavirdine Mesylate With Zidovudine and Didanosine Compared With Two-Drug Combinations of These Agents in Persons With HIV Disease With CD4 Counts of 100 to 500 cells/mm3 (ACTG 261)
Friedland G, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M. Efficacy and Safety of Delavirdine Mesylate With Zidovudine and Didanosine Compared With Two-Drug Combinations of These Agents in Persons With HIV Disease With CD4 Counts of 100 to 500 cells/mm3 (ACTG 261). JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 21: 281-292. PMID: 10428106, DOI: 10.1097/00126334-199908010-00005.Peer-Reviewed Original ResearchConceptsCells/mm3CD4 cell countTwo-drug combinationsCell countHIV-1 RNA changesHIV-1 RNA levelsMonths of monotherapyThree-drug regimenTwo-drug armTwo-drug regimensGastrointestinal side effectsThree-drug combinationDelavirdine mesylateNon-nucleoside reverseCD4 countCD4 cellsHIV diseaseKey efficacyMulticenter trialCopies/Antiretroviral activityHIV-1Side effectsDidanosineZidovudine